Related Experiment Video
Updated: May 10, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Molecular property prediction using pretrained-BERT and Bayesian active learning: a data-efficient approach to drug
Muhammad Arslan Masood1, Samuel Kaski2,3, Tianyu Cui2
1Department of Computer Science, Aalto University, Espoo, Finland. arslan.masood@aalto.fi.
Abstract:
In drug discovery, prioritizing compounds for experimental testing is a critical task that can be optimized through active learning by strategically selecting informative molecules. Active learning typically trains models on labeled examples alone, while unlabeled data is only used for acquisition. This fully supervised approach neglects valuable information present in unlabeled molecular data, impairing both predictive performance and the molecule selection process. We address this limitation by integrating a transformer-based BERT model, pretrained on 1.26 million compounds, into the active learning pipeline. This effectively disentangles representation learning and uncertainty estimation, leading to more reliable molecule selection. Experiments on Tox21 and ClinTox datasets demonstrate that our approach achieves equivalent toxic compound identification with 50% fewer iterations compared to conventional active learning. Analysis reveals that pretrained BERT representations generate a structured embedding space enabling reliable uncertainty estimation despite limited labeled data, confirmed through Expected Calibration Error measurements. This work establishes that combining pretrained molecular representations with active learning significantly improves both model performance and acquisition efficiency in drug discovery, providing a scalable framework for compound prioritization. SCIENTIFIC CONTRIBUTION: We demonstrate that high-quality molecular representations fundamentally determine active learning success in drug discovery, outweighing acquisition strategy selection. We provide a framework that integrates pretrained transformer models with Bayesian active learning to separate representation learning from uncertainty estimation-a critical distinction in low-data scenarios. This approach establishes a foundation for more efficient screening workflows across diverse pharmaceutical applications.
More Related Videos
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Prodrugs
Prodrugs help overcome...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...